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Abstract
Background: For Comparative Effectiveness Research (CER) there is a need to develop scales for appraisal of available
clinical research. Aims were to 1) test the feasibility of applying the pragmatic-explanatory continuum indicator summary
tool and the six CER defining characteristics of the Institute of Medicine to RCTs of acupuncture for treatment of low back
pain, and 2) evaluate the extent to which the evidence from these RCTs is relevant to clinical and health policy decision
making.
Methods: We searched Medline, the AcuTrialsTM Database to February 2011 and reference lists and included full-report
randomized trials in English that compared needle acupuncture with a conventional treatment in adults with non-specific
acute and/or chronic low back pain and restricted to those with $30 patients in the acupuncture group. Papers were
evaluated by 5 raters.
Principal Findings: From 119 abstracts, 44 full-text publications were screened and 10 trials (4,901 patients) were evaluated.
Due to missing information and initial difficulties in operationalizing the scoring items, the first scoring revealed inter-rater
and inter-item variance (intraclass correlations 0.02–0.60), which improved after consensus discussions to 0.20–1.00. The 10
trials were found to cover the efficacy-effectiveness continuum; those with more flexible acupuncture and no placebo
control scored closer to effectiveness.
Conclusion: Both instruments proved useful, but need further development. In addition, CONSORT guidelines for reporting
pragmatic trials should be expanded. Most studies in this review already reflect the movement towards CER and similar
approaches can be taken to evaluate comparative effectiveness relevance of RCTs for other treatments.
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Introduction
Comparative Effectiveness Research (CER) has considerable
potential to help health care providers as well as patients and
clinicians to choose among currently available therapeutic
options. Different definitions for CER have been published. In
this paper we use the working definition as established by the
Institute of Medicine (IOM) Committee, which defines CER as
‘‘the generation and synthesis of evidence that compares the
benefits and harms of alternative methods to prevent, diagnose,
treat, and monitor a clinical condition or to improve the delivery
of care. The purpose of CER is to assist consumers, clinicians,
purchasers, and policy makers to make informed decisions that
will improve health care at both the individual and population
levels’’ [1].
However, to date, the majority of clinical trials have assessed the
efficacy of medical interventions rather than their effectiveness. To
support more informed decision-making, there has been a call for
more evidence on real world effectiveness from CER [2].
Available systematic reviews generally do not assess available
evidence from a CER perspective – in other words, to examine the
extent to which published trials are relevant to clinical and health
policy decision making. On the contrary, appraisal of internal
validity plays one of the most prominent roles in systematic
reviews. For example, Cochrane reviews provide systematic
information about possible bias within each study, but do not
provide systematic information about the relevance of the study
results for clinical and health policy decision-making.
For a better understanding of CER, it is essential to distinguish
between ‘efficacy’ and ‘effectiveness’. ‘Efficacy’ refers to ‘‘the
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e32399
extent to which a specific intervention is beneficial under ideal
conditions’’ [3]. Many randomized controlled trials are efficacy
trials, particularly those conducted for regulatory drug approval.
They aim to produce the expected result for an intervention under
carefully controlled conditions chosen to maximize the likelihood
of observing an effect if it exists. The trial population and setting of
efficacy trials can differ in important ways from the clinical settings
in which the interventions are likely to be used [4]. By contrast,
‘effectiveness’ is a measure of the extent to which an intervention,
when deployed in the field in routine circumstances, does what it is
intended to do for a specific population [3], and therefore can
often be more relevant to policy evaluation and the health care
decisions of providers and patients.
For randomized trials, the distinction between explanatory and
pragmatic randomized trials was introduced in the 1960 s by
Schwarz and Lelloch [5] and is also used in the CONSORT
extension [6], another milestone publication on practical trials [7]
and the pragmatic-explanatory continuum indicator summary
(PRECIS) [8]. However, the term ‘explanatory’ can be misleading
since pragmatic trials can also use an explanatory (confirmatory)
statistical approach. Because of this potential confusion, we will
use the terms ‘efficacy’ and ‘effectiveness’ for labeling the ends of
this continuum. It is important to note that there is no sharp
distinction between efficacy and effectiveness trials. Rather these
terms exist in a continuum and the site along this continuum may
differ for different features of the trial design.
This is reflected in the PRECIS tool [8] that was primarily
developed to guide the design of RCTs along 10 dimensions of the
efficacy-effectiveness continuum. In addition, the IOM has
described six characteristics of CER (see Table 1) [1]. Both sets
of criteria share the intent of describing the features of research
that help inform clinical and health policy decisions. Use of these
tools to assess existing trials may offer insights about the specific
ways in which existing research has fallen short, and provide
specific ideas about how to improve the quality and relevance of
future trials. It is of major interest whether the available research
can inform stakeholders. Do the existing criteria that define
‘pragmatism’ and CER that were developed for planning trials
that inform clinical decision could be applied to the published
trials as a means of evaluating and strengthening the evidence base
for CER? Licensing drug trials usually have their main focus on
efficacy, using placebo controls and objective outcome measures
whenever possible. Because of these regulatory aspects, non-
pharmacological studies would serve as better examples to show
the whole range of an existing efficacy-effectiveness continuum.
CER is especially valuable for those disorders that are the most
common and most costly to society, have the highest morbidity
rates, and a great degree of variation in their practice [9]. Low
back pain has a high lifetime prevalence, is one of the most
common reasons for visits to a physician [10] and results in high
health care expenses [11]. An estimated 8 million Americans have
used acupuncture as a treatment for persistent disabling pain
conditions that include chronic low back pain [12], and clinical
relevance of acupuncture for chronic low back pain in usual care is
highlighted by a recent clinical expertise paper on acupuncture for
chronic low back pain in the New England Journal of Medicine
[13]. In this paper, we explore the efficacy/effectiveness
continuum in the context of RCTs that assess the impact of
acupuncture on low back pain.
This systematic review aims to 1) test the feasibility of applying
the PRECIS tool and the IOM CER characteristics to RCTs of
acupuncture for treatment of low back pain, and 2) evaluate the
extent to which the evidence from these RCTs is relevant to
clinical and health policy decision making.
Methods
Data sources and searches
We identified trials using the following search strategy:
N AcuTrialsTM Database [14] Feb 10, 2011 searched for low
back pain and a comparator group, which was standard care/
usual care or no treatment. This database was created by the
Research Department, Oregon College of Oriental Medicine,
Portland, OR as a comprehensive database that includes all
RCTs and systematic reviews on acupuncture published in
English.
N Medline 1966 to Feb 17, 2011 searched for ‘back pain and
acupuncture’ or ‘back pain and Chinese Medicine’ or ‘back
pain and Traditional Chinese Medicine’ using the limits
Clinical Trial, Meta-Analysis, Randomized Controlled Trial,
English.
N Hand-searching for applicable trials, including the two most
recent meta-analyses [15,16].
Study selection
Types of trials. We included controlled trials in which
allocation to treatment was explicitly randomized. Trials were
excluded that used an inappropriate method of randomization,
e.g. open alternation or lottery.
Types of participants. Trials conducted among adult
patients suffering from non-specific acute and/or chronic low
back pain were included. Trials including patients with specific low
back pain, e.g., sciatica or pelvic and lumbar pain during
pregnancy, were excluded.
Types of interventions. The treatments considered had to
at least involve needle insertion at acupuncture points, pain points
or trigger points, and be described as acupuncture. The control
interventions considered were conventional treatments (drugs,
relaxation, physical therapies, self care etc.). Trials with additional
acupuncture interventions based on usual care or other
conventional interventions were included. Trials in which
patients in the control group had no treatment or only rescue
medication or TENS were excluded because they were not
considered adequate conventional treatment interventions.
Types of publications. We included only English-language
full papers that reported results of single trials. Follow-up
publications, protocol publications, diagnostic trials, publications
on intervention details, and publications that reported only
economic results were excluded.
Sample size. Because we were mainly interested in the
efficacy-effectiveness continuum and due to higher variance it is
difficult to assess effectiveness with very small samples, we
predefined arbitrary to include only those RCTs with $30
patients in the acupuncture group.
Data Extraction and Quality Assessment
Selection of trials and preliminary data extraction were
performed by one rater (CMW). As a first step, references
retrieved from Medline and the AcuTrials database were
combined and duplicates were removed. All remaining abstracts
were screened and trials that were clearly irrelevant were excluded
(e.g., specific low back pain, only sham control or no control
group, see Figure 1 for details). In addition, reference lists of recent
systematic reviews [15,16] were checked, but did not reveal further
unique trials. For the abstracts meeting inclusion criteria, the full
papers were obtained and were formally re-checked to exclude
ineligible papers. Information on methods, patients, interventions,
Systematic Review Using CER Measures
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Table 1. Rating details using the PRECIS criteria and the IOM characteristics.
criteria
Rating#
max. diff.
points
Intraclass-
correla-
tion before/
after
operationa-
lization* good/
moderate/
difficult comment suggestions
PRECIS criteria
1) eligibility criteria 1 2.12/.59 moderate raters need good medical knowledge
about the range of patients with this
diagnosis in usual care
treatment guidelines
could be used to aid
decision making
2) treatment flexibility
intervention group
0 .82/1.00 good usual care situation differs in
countries and even US States,
number of treatment always limited
in interventional trials
more details in CONSORT
guidelines
3) practitioner expertise
intervention group
1 .10/.69 moderate expertise range differs between
countries and even US States, often
no data about usual care setting and
limited information about selection
procedure
more details in CONSORT
guidelines
4) treatment flexibility
control group
1 .58/.95 moderate publications often don’t provide
enough information about co-
interventions, number of treatment
always limited in interventional trials
more details in CONSORT
guidelines
5) practitioner expertise
control group
1 .60/.92 moderate publications don’t provide enough
information, expertise range differs
between countries and even US
States, often no data about usual
care setting and limited information
about selection procedure
more details in CONSORT
guidelines
6) follow up intensity 1 .02/.36 difficult trial situation always differs from
usual care, influence of telephone
interviews, or questionnaires is
difficult to operationalize
clear operationalization
needed
7) outcomes 1 2.20/2.20 difficult raters need good knowledge about
valid outcomes for the diagnosis,
usual care situation on one end of
the scale with no interference was
difficult
more diagnoses specific
standards e.g. in treatment
guidelines needed
8) patients’ compliance 2 .28/.62 difficult publications don’t provide enough
information
could be included in
CONSORT guidelines
9) practitioners’ protocol
adherence
1 .29/.68 difficult publications don’t provide enough
information
could be included in
CONSORT guidelines
10) primary analysis 1 2.12/.77 good older publications do not provide
this information systematic, most
trials do ITT and the relevant topic
of subgroup analyses is missing in
PRECIS
aspect of subgroup analysis
should be included (see IOM)
IOM criteria
1) directly informing a specific
clinical decision from the
patient perspective or a
health policy decision from
the population perspective
3 2.17/.03 moderate depends on health system,
interpreted differently from different
perspectives
2) comparing at least two
alternative interventions, each
with the potential to be ‘‘best
practice
2 2.09/.24 moderate raters need good medical knowledge
about treatments options and
standards, treatment standards differ
between countries, alternatives could
be whole treatment packages and
also usual care
treatment guidelines
could be used to aid
decision making
3) describing results at the
population and subgroup
levels
0 2.21/1.00 moderate publications provide often none only
partial results (e.g. p value for effect
modification), items can be easily
clearer operationalized
Data on effect
modification, but also
results for subgroups
needed, should be
included in CONSORT
guidelines
4) measuring outcomes—both
benefits and harms—that are
important to patients
2 2.19/1.00 moderate raters need good knowledge about valid
outcomes for the diagnosis, difficult to decide
which emphasis outcome and safety has in the
rating
more diagnoses specific
standards e.g. in
treatment guideline
needed that could linked
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outcomes and results was extracted from the included trials and
entered into an Excel spreadsheet. Special attention was given to
sample size, details and rationale of the intervention and
comparator groups, the terminology used (efficacy or effective-
ness), the test hypothesis (non-inferiority or superiority) and the
effect size. If the effect size was not given in the original
publications, it was extracted from published meta-analysis.
Data syntheses and analyses
The protocol of the systematic review was predefined. For all
included trials, the efficacy-effectiveness continuum was assessed
using both the ten PRECIS criteria [8] and the six Institute of
Medicine (IOM) defining characteristics of CER [17] To allow a
clearer approach, we converted the terminology from ‘explanato-
ry/pragmatic’ to ‘efficacy/effectiveness.’ Assessment of trials
(Table 2) was performed independently by 5 raters using an
enhanced quantified version of the PRECIS and IOM character-
istics with a scale of 1–5 for each criterion (1 =maximal efficacy to
5 =maximal effectiveness). This allowed calculation of inter-rater
correlations and to present results in figures. The five raters came
from different backgrounds (MD and PhD), each had more than
10 years of experience in clinical research, had worked on aspects
of research methodology, and had experience in systematic
reviews and acupuncture trials. Rating was done independently,
results were sent from each rater to CMW, and RL performed the
statistics. For the final results, each item was discussed in a
conference call between all raters until a consensus was reached.
Agreements between raters (inter-rater reliability) were calcu-
lated separately for each item and each time point (before and
after the consensus conference) by intraclass-correlations as
defined by Shrout and Fleiss [18].
Results
Search Results
Altogether, 119 abstracts were identified: 115 from Medline and
4 additional from the AcuTrialsTM database; no further unique
abstracts were identified from the recent systematic reviews. Of
these abstracts, 44 full papers were screened, and 10 trials,
including 4901 total patients (2482 acupuncture and 2419 control)
met the eligibility criteria and were subjected to data extraction
(see Figure 1).
Included trials
One trial focused on acute low back pain [19], while all the
others were on chronic pain low back pain. One trial included two
acupuncture groups: a standardized group and an individualized
acupuncture group [20]. For this analysis, we used the
individualized acupuncture group because we assumed this group
to be closer to usual care. Within the 10 trials, four included a
sham acupuncture group [21–24] and four included an economic
analysis [22,25–27]. Only two trials used a complex intervention.
In the trial by Cherkin [28], other Chinese medicine interventions
such as cupping and moxibustion, were allowed. However, in the
trial by Szczurko [29], acupuncture was delivered within a
naturopathic treatment, which included exercise and dietary
advice. All trials tested for superiority of acupuncture treatment.
None of the trials aimed to evaluate the non-inferiority of
acupuncture compared to conventional care. All ten trials were
published in peer reviewed medical journals with relevant impact
(Arch Int Med, BMJ, Am J Epi, Pain, PLOS One, Rheumatology,
Spine).
Interrater Reliability of Ratings
Raters judged the general difficulty of applying the criteria on a
scale from 0–10 (0= very easy; 10 = very difficult) as 6 (median;
range 2–7) for PRECIS and 8 (median; range 6–10) for the IOM
criteria. The first independent ratings of the efficacy-effectiveness
continuum were highly heterogeneous between trials and between
raters. This resulted in low inter-rater reliability estimates (Table 2).
Missing information in the publications and difficulties in
operationalizing the criteria were cited most frequently as the
main reasons for the high rater variation in initial scoring of the
trials (Table 1). Improved inter-rater reliability was found after the
consensus discussion. The consensus process benefitted from each
rater’s experience in conducting and/or assessing trials on low
back pain and acupuncture. Although there was still no full
consensus between raters, the maximum difference was 2 points.
Mean Ratings of the Efficacy – Effectiveness Continuum
Details on the trials are presented in Table 2. The trials by
Thomas et al [27] and Witt et al [26] that compared adjunctive
acupuncture to usual care alone had high effectiveness scores on
the efficacy-effectiveness continuum and could serve as examples
for trials that aim to represent a usual care situation, whereas those
trials which included an additional sham control arm
[20,21,23,24] had higher efficacy scores representing a more
experimental approach. This corresponded to the wording in the
papers: Only those trials that included a sham control arm used
the term ‘efficacy;’ all other trials used the term ‘effectiveness’.
Interestingly, most trials that scored higher on the efficacy side of
the continuum were less standardized than usually observed in
criteria
Rating#
max. diff.
points
Intraclass-
correla-
tion before/
after
operationa-
lization* good/
moderate/
difficult comment suggestions
5) employing methods and data
sources appropriate for the
decision of interest
1 2.03/.03 moderate publications don’t provide enough information
about the rational and setting for trial question
6) conducted in settings that are
similar to those in which the
intervention will be used in
practice.
2 .37/.69 moderate publications don’t provide enough information
about usual setting for the intervention, setting
differs between countries
more details in
CONSORT guidelines
#after consensus max difference of points (scale 1–5, 1 =max. efficacy to 5 =max. effectiveness) for each of the trials for this criteria,
*qualitative result from the discussion within the consensus procedure.
doi:10.1371/journal.pone.0032399.t001
Table 1. Cont.
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drug research. The results showed that, for each trial, the
placement along the efficacy-effectiveness continuum is multi-
dimensional and varied for the different criteria within a given trial
(Figure 2). Overall, when evaluating acupuncture as an adjunctive
treatment that allowed more flexible treatment protocols, trials
had higher effectiveness scores than trials that evaluated
acupuncture as a treatment alternative and used a more
standardized treatment protocol (Figure 2).
An interesting exploratory observation is that those trials that
reported more narrow eligibility criteria and a more standardized
acupuncture intervention [23,24,30] resulted in larger effect sizes
($0.5, Table 2) than trials that reported a more heterogeneous
Figure 1. Study selection.
doi:10.1371/journal.pone.0032399.g001
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patient sample and a flexible acupuncture treatment (effect
size#0.5, Table 2) [26,27].
Discussion
Using available criteria for planning CER to evaluate the
efficacy-effectiveness continuum of published trials resulted in
large heterogeneity between raters and items, which was partly
solved by a consensus procedure. This was mainly due to
information missing from the publications and to difficulties in
operationalizing the criteria. Our focus on RCTs assessing
acupuncture for low back pain allowed the inclusion of a number
of high quality trials representing a broad spectrum of clinical
research in the efficacy-effectiveness continuum. Trials that have a
more flexible acupuncture treatment protocol and no further
placebo control arm scored closer to effectiveness.
This is a systematic analysis that has tested the feasibility of
appraising the efficacy-effectiveness continuum of randomized
controlled trials. Advantages of the systematic review include its
innovative scope on the process of appraisal, high quality studies
covering the efficacy-effectiveness continuum, and that the scoring
was done by 5 independent raters using two different sets of
criteria. The review process benefitted from the experience of the
selected raters in the design, performance and/or assessment of
the field of research. Discussions between raters improved the
inter-rater reliability significantly. This underlines the complex
aspects of the efficacy-effectiveness continuum and the need for
rater training. Limitations were that only one rater selected the
papers, that secondary papers (e.g., on treatment details) were not
included, and that randomized trials are only one part of CER and
do not represent the whole spectrum of evidence. However,
Cochrane reviews, which are often used to assist in decision-
making, also focus on RCTs and primarily concentrate on the
main paper presenting the results. Another limitation is that both
criteria lists (PRECIS and IOM) were developed to guide new
trials and not to assess published trials. However, the present study
provides insights into the advantages and limitation of single items
and indicates that, following the definition and main character-
istics of CER, the ten PRECIS criteria and six IOM characteristics
seem plausible candidates for the evaluation of existing research
and could form a basis for a future evaluation instrument. That the
items of the PRECIS tool have relevance for appraising published
studies is supported by the very recent review by Koppenaal et al
[31]. The authors used the PRECIS tool on two meta-analyses,
scored the single items, and came to the conclusion that PRECIS
can provide useful estimates on how single studies and the whole
review are placed within the efficacy effectiveness continuum.
Interestingly the authors used a similar scale from 1 to 5. However,
they did either provide information on inter-rater variability nor
details on advantages and limitations of single PRECIS items
which can inform its further development.
The origin of some of the effect sizes presented in this review
could be seen as a limitation. It was not the aim of this review to
perform a meta-analysis and because of this effect sizes were taken
from the literature and only used as an exploratory aspect for
orientation.
The present findings reveal that the place of a trial in the
efficacy-effectiveness continuum is multidimensional, indicating it
is even more complicated to unambiguously label a trial as efficacy
or effectiveness. From the scoring of the trials, it is clear that two of
the RCTs [26,27] were designed mainly as effectiveness trials,
whereas others were designed more as efficacy trials [23,24,29].
Interestingly, two of the trials [20,21], both including a sham
control, standardized their acupuncture intervention much more
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than their conventional treatment control. None of the trials
included all available patients, but eligibility criteria varied from
relatively narrow to relatively wide.
In the early 1970’s, when Asian medicine including acupunc-
ture began its most recent migration to the West, researchers
adopted the randomized controlled trial to investigate acupunc-
ture without knowing Asian medicine had a long history [32].
Because of this evidence from those trials was often rejected as
invalid and was therefore ignored. The discussion and demand for
evidence that is generated in a way that satisfies decision-making
started early [33] and most studies in this review already reflect the
movement toward an evidence base that can inform decisions
makers. Acupuncture for low back pain can serve as a good
example for different options of randomized studies within CER.
On one hand, both large studies that evaluated acupuncture as
adjunct to usual care represent a unique way that RCTs can more
closely reflect the reality of a usual care setting [26,27]. On the
other hand, those trials that had both a standard care/usual care
control and a sham control arm, but still tried to keep their
acupuncture intervention more flexible are good examples for a
Figure 2. PRECIS scoring for the 10 included trials comparing different methodological aspects (second rating after consensus
procedure), a larger rounder figure would correlate with a higher score on PRECIS representing more the effectiveness side.
doi:10.1371/journal.pone.0032399.g002
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middle ground in the efficacy-effectiveness continuum [21].
Overall, the last decade of the acupuncture studies on low back
pain provides useful information for the design of future
randomized trials in other fields of non-pharmacological research.
In the scoring process of the trials appraising the eligibility
criteria was not always easy. Therefore, it would be useful to
analyze heterogeneity in addition to get better knowledge about
the population in the studies [34]. It is important that trials with
more heterogeneous populations result in higher outcome
variances and smaller effect sizes, which must be taken into
account when planning the sample sizes for future trials assessing
CER.
Furthermore, CER is susceptible to systematic error [35]. The
attempt to achieve methodological purity can result in clinically
meaningless results, while attempting to achieve full generalizabil-
ity can result in invalid and unreliable results. Achieving a creative
tension between the two is crucial [36] and the relevance of the
results has to be put into accordance with the rigor of the results.
In CER, the evaluation of effect modifications and stratifications
play a crucial role [37] to allow for conclusions on specific
subgroups. This is one of the IOM criteria, but was not
represented in the PRECIS score. Although the trials in our
analysis were mainly published in high-ranking journals, none of
the trials that scored more on the effectiveness side of the
continuum gave detailed information about subgroups. For
decision-making, this aspect should be strengthened in future
trials and should be included in the criteria list for evaluation of the
efficacy-effectiveness continuum.
One problem that came up during the rater consensus
procedure was the information missing from the main publica-
tions. It is highly recommended to include in future review
processes also all available secondary papers. However, in the case
of the included studies information on selection procedure of
practitioners, as well as for patient compliance measures and
practitioner adherence to protocol would not have been complete.
In addition, it would be helpful to know more about the setting in
which the treatment is typically carried out in each respective
country and how much the trial setting differs from the clinical
treatment setting. Although standards for reporting clinical trials
(CONSORT [6], STRICTA [38]) mention the most relevant
aspects, the above mentioned aspects, such as describing the usual
setting for this treatment in detail and providing clear information
on patients’ compliance and practitioner adherence, are not
adequately represented in the CONSORT guidelines and should
be discussed in future revisions.
Conclusion
It is of high relevance for stakeholders to appraise the extent to
which published trials are relevant to clinical and health policy
decision-making. A systematic instrument, which can be also used
in systematic reviews, needs further development. The available
instruments for planning randomized studies for CER could
provide a basis for this, but would need further development that
includes more defined operational criteria and a rater’s training
manual. In addition, CONSORT guidelines for reporting RCTs
should be more extended, fostering on reporting more details on
CER relevant aspects. Most studies in this review already reflect
the movement toward an evidence base that can inform both
decision-makers and provide useful information for the design of
randomized trials for other non-pharmacological treatments.
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